NOVARTIS logo.jpg
Novartis erzielt im zweiten Quartal weiterhin kräftige Umsatzsteigerungen und erhöht die Kerngewinnmarge; Gewinnprognose für das Geschäftsjahr 2024 angehoben
July 18, 2024 01:00 ET | Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs im zweiten Quartal um +11% (kWk1, +9% USD), das operative Kernergebnis verbesserte sich um +19% (kWk, +17% USD) Das Umsatzwachstum...
NOVARTIS logo.jpg
Novartis a poursuivi au T2 la forte croissance de son chiffre d’affaires et l’expansion de sa marge core; hausse des prévisions de son résultat opérationnel core pour 2024
July 18, 2024 01:00 ET | Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RC Résultats du deuxième trimestre (T2) Chiffre d’affaires net en hausse de +11% (tcc1, +9% USD) et du résultat opérationnel core, de +19% (tcc,...
NOVARTIS logo.jpg
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
July 18, 2024 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto...
NOVARTIS logo.jpg
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
May 31, 2024 08:00 ET | Novartis Pharma AG
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs....
NOVARTIS logo.jpg
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET | Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Dr. May Lynn Quan
Ground-breaking pilot project poised to transform breast cancer surgery in Alberta
May 27, 2024 12:00 ET | Calgary Health Foundation
Calgary, Alberta, Canada, May 27, 2024 (GLOBE NEWSWIRE) -- Calgary Health Foundation and Alberta Cancer Foundation announce $5.7M toward an innovative breast cancer surgery pilot project. The...
NOVARTIS logo.jpg
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024 06:15 ET | Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
NOVARTIS logo.jpg
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
May 25, 2024 06:00 ET | Novartis Pharma AG
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
May 22, 2024 01:00 ET | Sandoz Group
  Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all...
NOVARTIS logo.jpg
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
May 16, 2024 05:27 ET | Novartis Pharma AG
Novartis secured 79.6 percent acceptance by MorphoSys shareholders during the initial acceptance period, reaching the minimum 65% acceptance thresholdSettlement of the shares tendered during the...